EverSource Wealth Advisors LLC Has $238,000 Stock Holdings in Veeva Systems Inc. (NYSE:VEEV)

EverSource Wealth Advisors LLC increased its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 316.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,134 shares of the technology company’s stock after acquiring an additional 862 shares during the period. EverSource Wealth Advisors LLC’s holdings in Veeva Systems were worth $238,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its holdings in shares of Veeva Systems by 138.9% in the 3rd quarter. Principal Financial Group Inc. now owns 2,179,284 shares of the technology company’s stock valued at $457,366,000 after buying an additional 1,267,061 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Veeva Systems during the third quarter worth $526,000. Huntington National Bank lifted its stake in Veeva Systems by 19.8% in the third quarter. Huntington National Bank now owns 1,559 shares of the technology company’s stock valued at $327,000 after acquiring an additional 258 shares during the last quarter. Metis Global Partners LLC grew its position in shares of Veeva Systems by 13.1% in the 3rd quarter. Metis Global Partners LLC now owns 5,057 shares of the technology company’s stock valued at $1,061,000 after acquiring an additional 584 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Veeva Systems by 1.2% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,307 shares of the technology company’s stock worth $904,000 after purchasing an additional 50 shares during the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Veeva Systems Price Performance

Shares of NYSE:VEEV opened at $233.84 on Friday. Veeva Systems Inc. has a 1 year low of $170.25 and a 1 year high of $258.93. The stock has a market capitalization of $37.96 billion, a price-to-earnings ratio of 57.74, a price-to-earnings-growth ratio of 1.89 and a beta of 0.88. The company’s 50 day simple moving average is $227.12 and its 200 day simple moving average is $221.39.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Citigroup raised their target price on shares of Veeva Systems from $281.00 to $307.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Robert W. Baird lifted their target price on Veeva Systems from $283.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, March 6th. Barclays increased their price target on Veeva Systems from $260.00 to $275.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. KeyCorp reduced their price objective on shares of Veeva Systems from $285.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Finally, Piper Sandler increased their price objective on shares of Veeva Systems from $280.00 to $290.00 and gave the company an “overweight” rating in a research report on Friday, December 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $255.28.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.